Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies

Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies

CD40 agonists have been investigated as a strategy to awaken the immune system against cancers. Here, the authors use a virus encoding CD40L and tumour-associated antigens to enhance innate and adaptive immunity that together with tumour targeting antibodies controls the growth of tumours in mice.

Saved in:
Bibliographic Details
Main Authors: José Medina-Echeverz, Maria Hinterberger, Marco Testori, Marlene Geiger, Raphael Giessel, Barbara Bathke, Ronny Kassub, Fabienne Gräbnitz, Giovanna Fiore, Sonia T. Wennier, Paul Chaplin, Mark Suter, Hubertus Hochrein, Henning Lauterbach
Format: article
Language:EN
Published: Nature Portfolio 2019
Subjects:
Science
Q
Online Access:https://doaj.org/article/d593337aeba54d49978178381a7a20e5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/d593337aeba54d49978178381a7a20e5

Similar Items